Creative Planning buys $19,469,430 stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Creative Planning scooped up 21,314 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 12, 2016. The investment management firm now holds a total of 314,378 shares of Merck & Co. which is valued at $19,469,430.Merck & Co. makes up approximately 0.13% of Creative Planning’s portfolio.

Other Hedge Funds, Including , Atria Investments boosted its stake in MRK in the latest quarter, The investment management firm added 12,608 additional shares and now holds a total of 48,136 shares of Merck & Co. which is valued at $2,981,062. Merck & Co. makes up approx 0.28% of Atria Investments’s portfolio.Salem Capital Management Inc boosted its stake in MRK in the latest quarter, The investment management firm added 50 additional shares and now holds a total of 117,534 shares of Merck & Co. which is valued at $7,510,423. Merck & Co. makes up approx 4.15% of Salem Capital Management Inc’s portfolio.Pure Financial Advisors boosted its stake in MRK in the latest quarter, The investment management firm added 41 additional shares and now holds a total of 19,582 shares of Merck & Co. which is valued at $1,229,162. Merck & Co. makes up approx 0.40% of Pure Financial Advisors’s portfolio.Independent Portfolio Consultants reduced its stake in MRK by selling 2,110 shares or 9.07% in the most recent quarter. The Hedge Fund company now holds 21,144 shares of MRK which is valued at $1,327,843. Merck & Co. makes up approx 0.42% of Independent Portfolio Consultants’s portfolio.

Merck & Co. closed down -1.97 points or -3.08% at $61.93 with 1,39,55,380 shares getting traded on Tuesday. Post opening the session at $63.53, the shares hit an intraday low of $61.75 and an intraday high of $63.55 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.91. The company had revenue of $9844.00 million for the quarter, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.

Many Wall Street Analysts have commented on Merck & Co.. Merck & Co. was Upgraded by BofA/Merrill to ” Buy” on Oct 13, 2016. Company shares were Reiterated by Barclays on Sep 9, 2016 to “Overweight”, Firm has raised the Price Target to $ 72 from a previous price target of $66 .Credit Suisse Upgraded Merck & Co. on Aug 8, 2016 to ” Outperform”, Price Target of the shares are set at $73.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.